Yes, ABBA that's the bet and the question I asked myself. We know if the proxy vote were to go through, Sk will no doubt delay until year end when he can award more options to team and himself.
So the bet now is because proxy voted down, no RS no options. Will this be enough to force him to do a deal soon.
I've also been digging into past complaints filed by shareholders. It seems like this management is basically going down a path until they are caught and put in jails they will continue to do what they do.
Past claim was that due to the 3 deaths and FDA hold on the phase 3 trial, enrollment was delayed. So the result released last summer was incomplete because half of the patients weren't even accounted for due to the delay. But, management said nothing about that to the public until later at the year end on second analysis which disclosed information about the other half of the patients which showed statistically significant.
That's clear as day management disclosed incomplete trial results without stating clearly the result was inconclusive. Then award themselves options prior to the good news were out.
Now they are proposing more options and RS prior to the NDA submission later this year which got shot down on the vote. Then there are talks of shareholders attempting to remove SK.
You are basically betting that a deal will be forced through now that RS and options is a no.
SCLC results are pretty much kept in the dark. Enrollment on that phase II was on time and no delays. Results should be available by now.
Market Data 
Markets 
AI
